Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Apr
12
Today In Oncology
Pausing vs Continuing BTK Inhibitors at Time of COVID 19 Vaccination in Patients With CLL
Neoantigen-Selected TILs Boost Response to Immunotherapy in Heavily Pretreated GI Cancers
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo